Evidence map›Paper›PMID 33537114›Full record

ReviewThe World Allergy Organization journal2021

Perspectives on decisions for treatment and care in severe asthma.

Tonya Winders, Jorge Maspero, Luke Callan, Mona Al-Ahmad

Open access · goldAbstract readReview
In one paragraph

Review in The World Allergy Organization journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Tonya WindersAllergy & Asthma Network/Global Allergy & Airways Patient Platform (GAAPP), Vienna, VA, USA.
Jorge MasperoAllergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina.
Luke CallanGlobal Market Access and Pricing, AstraZeneca UK Ltd., Cambridge, UK.
Mona Al-AhmadDepartment of Microbiology, Faculty of Medicine, Kuwait University, Kuwait.
AstraZeneca (United Kingdom) · GBKuwait University · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere asthma is a subtype of asthma that can be hard to control, resulting in an exceptional impact on an individual's quality of life. The aim of this review article is to explore the misalignment of perceptions of severe asthma among different stakeholders to identify how to reduce burden and improve delivery of care.

resultsThe misalignment of perspectives is best reflected in randomised controlled trials (RCTs) in asthma treatments, which are often designed for regulatory approval with a focus on exacerbations with no direct input from the individuals that the treatments are designed for. Based on a literature review and the clinical experience of the authors to overcome this disparity, the goals of people with severe asthma need to be incorporated throughout their care, from study design to the day-to-day management of their condition. Improved education for individuals and their support network will provide them with resources and knowledge so that they can effectively communicate their needs to other stakeholders involved in their care. CONCLUSION/RECOMMENDATION: A collaborative effort from all stakeholders is essential to ensure efficient management of asthma and a reduction in asthma burden on individuals and society.

Indexed as

BurdenPerspectiveSevere asthma

Identifiers

PMID33537114
PMCPMC7817505
OpenAlexW3122690990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.